Overview

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

Status:
Terminated
Trial end date:
2016-07-11
Target enrollment:
Participant gender:
Summary
This is a Phase I, open label, non randomized, multicenter study designed to investigate the safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in subjects with advanced HCC.
Phase:
Phase 1
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.